Large Study Finds No Increased Risk of Most Eye Disorders With Semaglutide, but Rare Vision Condition Signals Caution

A new analysis of nearly 74,000 patients suggests that the diabetes and weight-loss drug semaglutide does not raise the risk of diabetic retinopathy or other general eye disorders. However, the study identified a potential link to a rare condition called nonarteritic anterior ischemic optic neuropathy (NAION), highlighting a need for closer monitoring and further research.

Extensive Review of Clinical Trial Data

Semaglutide, a GLP-1 receptor agonist used to treat type 2 diabetes and, more recently, obesity, has earned attention for its effectiveness in blood sugar control and cardiovascular benefits. But in recent years, individual studies have raised concerns over possible links to certain ocular complications, including worsening diabetic retinopathy and NAION, a sudden, painless vision loss caused by reduced blood flow to the optic nerve.

The new systematic review and meta-analysis examined 78 randomized controlled trials involving 73,640 participants. Researchers compared semaglutide with both placebo and active drug comparators, focusing on three outcomes: any ocular adverse event, diabetic retinopathy, and NAION. The patient populations ranged from individuals with long-standing type 2 diabetes to those with obesity but no diabetes.

Key Findings

The pooled data found no difference in overall eye disorder rates between patients taking semaglutide and those in control groups (odds ratio [OR] 1.01; 95% confidence interval [CI], 0.91–1.12). Similarly, there was no change in diabetic retinopathy risk (OR 1.04; 95% CI, 0.92–1.17). The findings were consistent across different trial durations, baseline health conditions, and comparator types.

However, a different signal emerged when looking at NAION. While still a rare outcome, patients on semaglutide had higher odds of developing the condition (OR 3.92; 95% CI, 1.02–15.02). This translated to an estimated incidence of 60.7 cases per 100,000 participants, compared with 8.2 per 100,000 in control groups.

“These findings suggest that semaglutide was not associated with an increased risk of eye disorders or diabetic retinopathy. Despite the fact that an association between semaglutide treatment and NAION was found, current evidence remains insufficient to establish definitive conclusions regarding its association with NAION.”

Why NAION Matters

NAION is the most common cause of acute optic nerve-related vision loss in adults over 50. Risk factors include diabetes, hypertension, and high cholesterol, as well as smoking and certain anatomic features of the eye. Although the absolute risk remains low, the condition can cause permanent partial vision loss and has no proven treatment.

Prior observational studies have delivered mixed results on whether GLP-1 drugs like semaglutide contribute to NAION risk. One cohort study at a neuro-ophthalmology center suggested an elevated risk, while a large retrospective analysis across 21 countries found no association. A Danish study, however, reported more than a two-fold risk increase among people with type 2 diabetes. The new meta-analysis strengthens the statistical evidence for an association, but researchers caution that small case numbers mean results should be interpreted cautiously.

Study Limitations

Most trials in the analysis were not designed to specifically track eye complications, and many lacked standardized vision testing. Fundus photography or dilated eye exams were sometimes conducted at the start and end of a trial, but more sensitive tests such as optical coherence tomography or formal visual field assessments were rarely used. The rarity of NAION means that even large datasets might not capture the full scope of risk.

Another limitation: patients with advanced diabetic retinopathy requiring urgent treatment were typically excluded from these trials, which may understate risks in the highest-risk groups.

What This Means for Patients

For people with diabetes or obesity, the cardiovascular and metabolic benefits of semaglutide remain well established. Still, for individuals with known eye disease or multiple vascular risk factors, the findings suggest it may be prudent to discuss NAION risk with a physician, especially if sudden vision changes occur. The authors recommend that future clinical trials use standardized eye exams and include larger sample sizes to clarify whether semaglutide is a true risk factor for NAION.

In the meantime, experts emphasize that anyone taking semaglutide should be alert to rapid vision changes and seek immediate ophthalmologic evaluation, as early detection and diagnosis are key to managing rare but potentially serious eye complications.